Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (CMX001), a clinical-stage nucleotide analog, CMX157 which was licensed to ContraVir Pharmaceuticals in 2014, and early clinical candidates including CMX669.
|Apr 28, 2016||DEFA14A||definitive additional proxy materials|
|Apr 28, 2016||DEF 14A||definitive proxy statement|
|Apr 20, 2016||CT ORDER||confidential treatment order|
|Apr 5, 2016||4||mario, ernest|
|Mar 16, 2016||4||mario, ernest|
The Chimerix ticker is CMRX and it is traded on the Nasdaq Global Market.
2505 Meridian Parkway
Durham, NC 27713
You can view our Board of Directors by visiting the Board of Directors section of our Investor Relations website.
You can view our management team by visiting the Management section of our Investor Relations website.
Chimerix does not expect to declare or pay any cash or other dividends on our common stock.
Chimerix does not currently have a direct stock purchase plan.
The transfer agent and registrar for our common stock is:
Computershare Trust Company, N.A.
The transfer agent and registrar’s address is:
P.O. Box 43078
Providence, Rhode Island 02940
Please submit your question using the form below.